111 Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups

Mazurek, Henryk; Chiron, R.; Pelikan, L; Geidel, C.; Bolbás, Katalin; Antipkin, Y.; Blanco, Michael; Varoli, Guido; Santoro, Debora; Cicirello, Helen; Чучалин, А. Г.

doi:10.1016/s1569-1993(11)60128-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two clinical trials performed with TIS 300 mg/4 mL in chronically infected CF patients also revealed that treatment produced a significant improvement in forced expiratory volume in 1 second (FEV 1 ). 26 , 27 Mazurek et al 28 , 33 compared TIS 300 mg/5 mL with TIS 300 mg/4 mL in 321 patients and found improved FEV 1 in both arms.…”

Section: Administration Of Inhaled Tobramycinmentioning

confidence: 99%

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

Vázquez-Espinosa

Girón

Gómez-Punter

et al. 2015

TCRM

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a fatal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene whose mortality is conditioned by a progressive decline in lung function. Bacterial infections play a key role in this decline. Chronic bacterial infection in CF patients varies over time and the presence of Pseudomonas aeruginosa in sputum is a marker of poor prognosis. P. aeruginosa is eradicated from the airways using inhaled antibiotics administered in various formulations and devices. Antipseudomonal antibiotics have extended the survival of CF patients to 40 years. Tobramycin is a bactericidal aminoglycoside antibiotic with demonstrated activity against gram-negative microorganisms. Initially, the drug was administered as an inhaled parenteral solution. Subsequently, a specific tobramycin inhalation solution was developed. PulmoSphere™ technology enables dry tobramycin powder to be formulated for inhalation (tobramycin inhalation powder) using a small and portable capsule-based breath-activated device (T-326). Chronic colonization by P. aeruginosa is the main indication for aerosol antibiotic therapy. The American Cystic Fibrosis Foundation, European guidelines, and Spanish consensus guidelines provide different recommendations for eradication.

show abstract

Section: Administration Of Inhaled Tobramycinmentioning

confidence: 99%

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

Vázquez-Espinosa

Girón

Gómez-Punter

et al. 2015

TCRM

View full text Add to dashboard Cite

show abstract

111 Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups

Cited by 1 publication

References 0 publications

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

Contact Info

Product

Resources

About

111 Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups

Cited by 1 publication

References 0 publications

Long-term safety and efficacy of tobramycin in the&nbsp;management of cystic fibrosis

Long-term safety and efficacy of tobramycin in the&nbsp;management of cystic fibrosis

Contact Info

Product

Resources

About

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis